《EAU男性下尿路症状诊治指南(2012年版)》解读(3)
第1页 |
参见附件。
\[1\]Brown CT, Yap T, Cromwell DA, et al. Self-management for men with lower urinary tract symptoms-a randomised controlled trial. BMJ, 2007(6):334.
\[2\]Djavan B, Chapple C, Milani S, et al. State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology, 2004,64(6):1081-1088.
\[3\]Michel MC, Mehlburger L, Bressel HU, et al. Comparison of tamsulosin efficacy in subgroups of patients with lower urinary tract symptoms. Prostate Cancer Prost Dis,1998,1(6):332-335.
\[4\]McConnell JD, Roehrborn CG, Bautista O, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med,2003,349(25):2387-2398.
\[5\]Donohue JF, Sharma H, Abraham R, et al. Transurethral prostate resection and bleeding: a randomised, placebo controlled trial of the role of finasteride for decreasing operative blood loss. J Urol,2002,168(5):2024-2026.
\[6\]Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol,2006,49(4):651-658.
\[7\]Michel MC, Schneider T, Krege S, et al. Does gender or age affect the efficacy and safety oftolterodine? J Urol,2002,168(3):1027-1031.
\[8\]Kaplan SA, Walmsley K, Te AE. Tolterodine extended release attenuates lower urinary tract symptoms in men with benign prostatic hyperplasia. J Urol,2005,174(6):2273-2275.
您现在查看是摘要介绍页,详见PDF附件(4078kb)。